PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: PrimeSyn Lab, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

PrimeSyn Lab Expands Operation and Growth Prompts for Move to New Larger Quarters - PrimeSyn Lab, Inc. expands its operation and moves to a new location. The company provides contract lab services which focuses in the areas of Organic synthesis, GMP oligos, Analytical lab services, Proteins and educational services
PrimeSyn Lab Expands Operation and Growth Prompts for Move to New Larger Quarters

 

NewswireToday - /newswire/ - Hillsborough, NJ, United States, 2007/01/19 - PrimeSyn Lab, Inc. expands its operation and moves to a new location. The company provides contract lab services which focuses in the areas of Organic synthesis, GMP oligos, Analytical lab services, Proteins and educational services.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Since establishing the NJ operations in 2002, PrimeSyn Lab Inc. has grown considerably. "Our rapid expansion made us realize that we needed more space to meet our customer's needs and for future growth," said Dr. Chaturvedi, CEO, PrimeSyn Lab Inc. "We chose to locate our company within NJ to be readily available to our bio-pharmaceutical customers. With our new expanded operation, we feel we can support our customers and help them achieve their goals faster and more effectively."

Dr. Chaturvedi looks forward to expanding their laboratory educational offerings in their new facility, which houses a modern state of the art training center located at 9 Ilene Ct. Bldg 6, Unit 1 and 2 Hillsborough, NJ 08844.

About PrimeSyn Lab, Inc.

PrimeSyn Lab (primesyn.com) is a leader in the area of Custom DNA/RNA primer and probe synthesis and specializes in ULTRA PURE Oligonucleotides. PrimeSyn Lab is a FDA registered manufacturer for Analyte Specific Reagents (ASRs) and can provide GMPs custom oligo synthesis. PrimeSyn Lab also provides contract analytical lab services (e.g. including structural characterization of protein molecules, CD and fluorescent spectroscopy, mass spectral analysis, and small molecule analysis). Our expertise spans organic synthesis and analysis through method development. PrimeSyn Lab's products and services are used for contract research, product development and assay development within the Bio-pharmaceutical industry.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: PrimeSyn Lab, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


PrimeSyn Lab Expands Operation and Growth Prompts for Move to New Larger Quarters

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Corporate Affairs - PrimeSyn.com 
1-877-PRIME03 press[.]primesyn.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any PrimeSyn Lab, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From PrimeSyn Lab, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)